News

Hosted on MSN

Tempus AI Unveils New Liquid Biopsy Assay for Early Immunotherapy Response Monitoring in Cancer

On Monday, Tempus AI Inc. (NASDAQ:TEM) announced the introduction of xM for treatment response monitoring/TRM. This new liquid biopsy assay is designed to detect molecular responses to ...
ascopubs.org

Quantitative Multiplex Immunofluorescence Assay for Trophoblast Cell-Surface Antigen 2 and Human Epidermal Growth Factor Receptor 2 Expression in Breast Cancer: Toward Guiding ...

Phase II Trial of TAS-102 in Colorectal Cancer Patients With Circulating Tumor DNA-Defined Minimal Residual Disease After Adjuvant Therapy: INTERCEPT-TT A multiplex QIF assay was optimized on tissue ...
Medscape

Novel CTC Assay Detects Early-Stage Colorectal Cancer

SAN FRANCISCO — A novel assay for detecting circulating tumor cells (CTCs) holds potential as a screening test for colorectal cancer, because it detects the disease at an early stage, and even detects ...
Nasdaq

Natera Presents Data at ESMO GI on its Tissue-Free Latitude™ MRD* Assay, Demonstrating Excellent Overall Performance in Colorectal Cancer

AUSTIN, Texas--(BUSINESS WIRE)-- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced data from a colorectal cancer (CRC) study of its tissue-free ...